Recombinant Protein Market is Projected To Reach A Revised Size of USD 2,320.21 Million By 2029, Growing At A CAGR of 13.02%
Recombinant Protein Market?is segmented by Type - Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, Others,? by Application - Biopharmaceutical Companies, Academic and Research Institutes, Contract Research Organizations. Global Opportunity Analysis and Industry Forecast 2023-2029. It is published in Valuates Reports under the Pharmaceuticals & Biotech Category.
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Recombinant Protein estimated at USD 975.77 million in the year 2022, is projected to reach a revised size of USD 2,320.21 million by 2029, growing at a CAGR of 13.02% during the forecast period 2023-2029.
Major Factors Driving The Growth of The Recombinant Protein Market are
The recombinant protein market will expand over the projected period due to factors like the rise in the prevalence of chronic illnesses, an increase in consumer preference for biosimilars and biologics, and advancements in recombinant products.
Additionally, a larger sum is being spent on the research and development of the items that fall under the category of recombinant proteins, which is projected to spur recombinant protein market expansion in the years to come.
Browse The Table of Contents And List of Figures At?https://reports.valuates.com/reports/QYRE-Auto-11J3238/global-recombinant-protein
TRENDS INFLUENCING THE GROWTH OF RECOMBINANT PROTEIN MARKET
Recombinant proteins are used to treat a number of chronic disorders, including dwarfism, congestive heart failure, diabetes, cerebral apoplexy, myocardial infarction, multiple sclerosis, anemia, neutropenia, etc. They are also used in research. In addition, subsequent generations of recombinant proteins made some advancements over the prior generation. The second generation of recombinant proteins included proteins with improved qualities including selectivity, biodistribution, and effectiveness, similar to the previous generation, which included native protein structures. The third generation of recombinant proteins also included novel formulations and delivery methods with improved effectiveness and security. This factor is expected to drive the recombinant protein market.
The global healthcare industry is expanding rapidly, which encourages spending on research and development to find new treatments for a range of illnesses. Recombinant protein production is intimately correlated with the expansion of the healthcare industry and spending on biologics. Additionally, government support stimulated the research efforts of academic institutions and biotechnological companies, resulting in developments in the market for recombinant proteins. This factor is expected to drive the recombinant protein market.
As a result, due to increased research and development costs, an aging population, an increase in the frequency of chronic illnesses, a growing preference for biologics and biosimilars, and the introduction of sophisticated recombinant goods Over the projected period, the recombinant protein market is anticipated to see rapid expansion.
Get Your Sample Today:?https://reports.valuates.com/request/sample/QYRE-Auto-11J3238/Global_Recombinant_Protein_Market
RECOMBINANT PROTEIN MARKET SHARE ANALYSIS
Recombinant protein sales in North America were valued at USD 334.79 million in 2022 and are projected to increase to USD 736.53 million by 2029, at a CAGR of 11.75% from 2023 to 2029.
The recombinant protein market in Asia-Pacific was valued at USD 362.89 million in 2022 and will increase to USD 1,010.82 million by 2029, growing at a CAGR of 15.52% from 2023 to 2029.
The recombinant protein market in Europe was valued at USD 240.37 million in 2022 and would increase to USD 508.09 million by 2029, growing at a CAGR of 11.15% from 2023 to 2029.
The market share leader is the sub-segment for recombinant growth factors. Due to their numerous uses, recombinant growth factors have become more prominent in the market. Numerous recombinant growth factors have been demonstrated to hasten the healing of chronic wounds in diabetes individuals. Besides this, clinical nephrology is another area where recombinant growth factors are widely used.
Inquire For Customization:
Market By Region
Inquire For Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-11J3238/Global_Recombinant_Protein_Market
领英推荐
Key players
Inquire For Chapter Cost : https://reports.valuates.com/request/chaptercost/QYRE-Auto-11J3238/Global_Recombinant_Protein_Market
Buy Now for Single User + Covid-19 Impact :?https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-11J3238&lic=single-user
SUBSCRIPTION
We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.
SIMILAR REPORTS
-? Recombinant Plasma Protein Therapeutics Market?was valued at USD 7857.8 million in 2022 and is anticipated to reach USD 11310 million by 2029, witnessing a CAGR of 4.9% during the forecast period 2023-2029.
-? Synthetic Biology market?size is estimated to be worth USD 10060 million in 2022 and is forecast to be a readjusted size of USD 33120 million by 2028 with a CAGR of 22.0% during the review period.
-? Genome Editing & Genome Engineering Market? is projected to reach a revised size of USD 6739.8 million by 2028, growing at a CAGR of 9.3% during the forecast period 2022-2028.
-? Microfluidics Market is projected to reach USD 7397 million by 2028 from an estimated USD 3496.8 million in 2022, at a CAGR of 13.3% during 2023 and 2028.